SCHEMBL66631

SCHEMBL66631

[NH]CCNS(=O)(=O)c1ccc(Cl)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.62
NPSR1 Q6W5P4 1/20 0.62
ALDH1A1 P00352 4/20 0.57
KMT2A Q03164 4/20 0.57
MEN1 O00255 3/20 0.57
TP53 P04637 1/20 0.57
GAA P10253 1/20 0.57
KDM4E B2RXH2 1/20 0.57
CA1 P00915 3/20 0.53
CA2 P00918 3/20 0.53
CYP19A1 P11511 1/20 0.53
TBXA2R P21731 1/20 0.53
MAPT P10636 1/20 0.53
CA12 O43570 1/20 0.52
CA3 P07451 1/20 0.52
CA4 P22748 1/20 0.52
CA6 P23280 1/20 0.52
CA5A P35218 1/20 0.52
CA7 P43166 1/20 0.52
CA9 Q16790 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7023027 0.82 TSHR (0.64) TSHRNPSR1ALDH1A1KMT2AMEN1
SCHEMBL9577200 0.82 ALDH1A1 (0.68) TSHRNPSR1ALDH1A1KMT2AMEN1
SCHEMBL66632 0.81 CYP3A4 (0.70) TSHRNPSR1ALDH1A1KMT2AMEN1
SCHEMBL1148808 0.81 TSHR (0.67) TSHRNPSR1ALDH1A1KMT2AMEN1
SCHEMBL7920724 0.81 TSHR (0.67) TSHRNPSR1ALDH1A1KMT2AMEN1
SCHEMBL11883523 0.81 CA1 (0.68) TSHRNPSR1ALDH1A1KMT2AMEN1
SCHEMBL5352151 0.81 TSHR (0.62) TSHRNPSR1ALDH1A1KMT2AMEN1
SCHEMBL6006520 0.80 ALDH1A1 (0.68) TSHRNPSR1ALDH1A1KDM4ECA1
SCHEMBL7920697 0.79 ALDH1A1 (0.69) TSHRNPSR1ALDH1A1KMT2AMEN1
Hydrochloric Acid SCHEMBL1580080 0.79 CYP3A4 (0.68) TSHRNPSR1ALDH1A1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8865732-B2 Heterocyclic compounds and uses thereof NOVARTIS AG (CH) 2014-10-21 US disclosed
US-20130210818-A1 Novel Heterocyclic Compounds and Uses Thereof NOVARTIS AG (CH) 2013-08-15 US disclosed
US-8129394-B2 Heteroaryl-substituted imidazole compounds and uses thereof NOVARTIS AG (CH) 2012-03-06 US disclosed
EP-2274300-A2 NOVEL HETEROCYCLIC COMPOUNDS AND USES THEROF Novartis AG (CH) 2011-01-19 EP disclosed
US-20100003246-A1 Novel heterocyclic compounds and uses therof NOVARTIS AG (CH) 2010-01-07 US disclosed
WO-2009115572-A2 NOVEL HETEROCYCLIC COMPOUNDS AND USES THEROF NOVARTIS AG (CH) 2009-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100003246-A1 Novel heterocyclic compounds and uses therof BRAF, ARAF, KRAS TSHR 3286/4885NPSR1 4364/4885ALDH1A1 3257/4885
US-20130210818-A1 Novel Heterocyclic Compounds and Uses Thereof BRAF, RAF1, HRAS TSHR 3980/4885NPSR1 4625/4885ALDH1A1 2358/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.